A Pharmacodynamic Study of Oral eFT508 in Subjects With Advanced Triple Negative Breast Cancer and Hepatocellular Carcinoma
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2018
At a glance
- Drugs EFT 508 (Primary)
- Indications Advanced breast cancer; Liver cancer
- Focus Pharmacodynamics
- Sponsors Effector Therapeutics
- 30 May 2018 Status changed from recruiting to discontinued due to change in focus of the development program
- 12 Dec 2017 Status changed from not yet recruiting to recruiting.
- 07 Dec 2017 Planned initiation date changed from 1 Nov 2017 to 1 Dec 2017.